disorder, weight gain, bone fracture, and cataract. Frequency and time to onset was examined in each treatment group during the 12-week treatment period. RESULTS: The high dose prednisone SOC treatment group had a higher proportion 65.2% (15 of 23) of pre-defined events compared to 34.1% (15 of 44) in patients in the combined avacopan treatment groups (p ¼ 0.02). The greatest differences were seen in the frequencies of psychiatric disorders (26.1% vs 6.8%), hyperglycemia (13.4% vs 2.3%), weight gain >10 kg (8.7% vs 2.3%) and bone fractures or cataracts (each 4.3% vs 0%). Occurrence of new or worsening hypertension was similar across treatment groups (21.7% SOC, 22.7% avacopan). Of note, hypertensive events appeared more rapidly in SOC compared to avacopan groups (median time to onset 8 days for SOC vs 22 and 43 days with avacopan low dose and avacopan no prednisone, respectively), and the need to start or increase anti-hypertensive medication was greater with SOC vs avacopan treatment (100% vs 60%). All adverse events of hypertension were reported as mild or moderate. CONCLUSIONS: AAV patients treated with avacopan experienced fewer adverse events commonly associated with glucocorticoids in the CLEAR trial. Though limited by relatively small numbers of events, these results are consistent with the hypothesis that treatment with avacopan may reduce the morbidity associated with AAV treatment. This hypothesis will be further explored in the ongoing ADVOCATE trial to test avacopan treatment over 52 weeks in 300 patients.
INTRODUCTION AND AIMS:
In anti-glomerular basement membrane (anti-GBM) glomerulonephritis (GN) in rat, glomerular injury caused by activated macrophages (Mu) is induced by CD8 þ lymphocytes (CD8 þ Lym). However, little is known about the profile of CD8 þ Lym, with the exception that they do not express T-cell receptors or CD3. Innate lymphoid cells (ILCs), a recently discovered group of immune cells, are classified into group 1, group 2 and group 3 ILCs based on their phenotypic and functional characteristics of Th1, Th2 and Th17, respectively. Notably, ILCs lack myeloid and dendritic cell phenotypical markers. This study examined the profile of CD8 þ Lym, which show features similar to those of ILCs. In addition, we investigated the effects of peroxisome proliferator-activated receptor alpha (PPARa), which has anti-inflammatory effects on anti-GBM GN. METHODS: Three groups of 4-week-old male Wister-Kyoto rats were administered fenofibrate (300 mg/kg/day; PPARa agonist), pioglitazone (100 mg/kg/day; PPARc agonist) or vehicle, respectively, once daily from on day 0, and then injected intravenously with 50 lg anti-GBM antibodies on day 1. Urine and blood samples, and the kidneys were collected on day 8. Cell surface markers and cytokine expression of CD8 
METHODS:
One hundred twenty five patients were included in the retrospective study, 40% males; mean age 56614.3 years. Seventy (56%) patients were MPO-ANCA positive, 42 patients (34%) were PR3-ANCA positive, and 12 patients (10%) were ANCA negative. Serum creatinine (SCr) levels was 560 [390; 825] mmol/L, e-GFR at diagnosis was 7.5 [4.6; 12.5] ml/min/1.73 m(2), 73 patients (56%) required acute dialysis. According to the mode of induction therapy, the patients were divided into 3 groups: 94 patients were treated with GC and CYC (Group 1), 15 patients received GC and RTX (Group 2), 16 patients received GC, CYC and RTX (Group 3). The treated with RTX patients were older (62,2 612,9 vs 53.4614,9; p<0.05), had higher SCr levels (690 [470; 1025] vs 530 [377; 802] mmol/L; p<0.01), and differed by more significant glomerulo-(39620,1% vs 29,3624,8%; p<0.05) and tubulointerstitial sclerosis (45619,1% vs 33,6622,1%; p<0.05) . Three years patients and renal survival rate were evaluated RESULTS: Three-years patients survival rate were maximal in the Groups 1 and 2 (84% and 91% respectively, NS) and minimal in the Group 3 (31%, h<0,01). Three-years renal survival rate was significantly higher in the Group 1 (76%, h<0,01) and much lower in the Groups 2 (22%) and 3 (47%). CONCLUSIONS: In patients with severe kidney damage, the use of RTX in addition to GC or to combination GC with CYC does not enhance the efficacy of the latter. The adding of RTX to traditional therapy GC and CYC resulted in reducing patient's survival likely due to increased risk for infectious complications. 
